Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV
- PMID: 38691025
- PMCID: PMC11067998
- DOI: 10.1080/21645515.2024.2346390
Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV
Abstract
Middle East respiratory coronavirus (MERS-CoV) is a newly emergent, highly pathogenic coronavirus that is associated with 34% mortality rate. MERS-CoV remains listed as priority pathogen by the WHO. Since its discovery in 2012 and despite the efforts to develop coronaviruses vaccines to fight against SARS-CoV-2, there are currently no MERS-CoV vaccine that has been approved. Therefore, there is high demand to continue on the development of prophylactic vaccines against MERS-CoV. Current advancements in vaccine developments can be adapted for the development of improved MERS-CoV vaccines candidates. Nucleic acid-based vaccines, including pDNA and mRNA, are relatively new class of vaccine platforms. In this work, we developed pDNA and mRNA vaccine candidates expressing S.FL gene of MERS-CoV. Further, we synthesized a silane functionalized hierarchical aluminosilicate to encapsulate each vaccine candidates. We tested the nucleic acid vaccine candidates in mice and evaluated humoral antibodies response. Interestingly, we determined that the non-encapsulated, codon optimized S.FL pDNA vaccine candidate elicited the highest level of antibody responses against S.FL and S1 of MERS-CoV. Encapsulation of mRNA with nanoporous aluminosilicate increased the humoral antibody responses, whereas encapsulation of pDNA did not. These findings suggests that MERS-CoV S.FL pDNA vaccine candidate induced the highest level of humoral responses. This study will enhance further optimization of nanosilica as potential carrier for mRNA vaccines. In conclusion, this study suggests MERS-CoV pDNA vaccine candidate as a suitable vaccine platform for further pivotal preclinical testings.
Keywords: APTMOS; DPP-4; HAS; IM; MERS-CoV; RBD; SC; coronavirus; mRNA; pDNA; silica; spike; vaccine.
Conflict of interest statement
No potential conflict of interest was reported by the authors.
Figures
Similar articles
-
Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.J Virol. 2020 Nov 23;94(24):e01176-20. doi: 10.1128/JVI.01176-20. Print 2020 Nov 23. J Virol. 2020. PMID: 32967955 Free PMC article.
-
Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice.Viruses. 2020 Jan 20;12(1):125. doi: 10.3390/v12010125. Viruses. 2020. PMID: 31968702 Free PMC article.
-
Antibodies and vaccines against Middle East respiratory syndrome coronavirus.Emerg Microbes Infect. 2019;8(1):841-856. doi: 10.1080/22221751.2019.1624482. Emerg Microbes Infect. 2019. PMID: 31169078 Free PMC article. Review.
-
Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism.Viruses. 2019 Jan 17;11(1):74. doi: 10.3390/v11010074. Viruses. 2019. PMID: 30658390 Free PMC article. Review.
-
ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.Vaccine. 2017 Jun 27;35(30):3780-3788. doi: 10.1016/j.vaccine.2017.05.032. Epub 2017 Jun 1. Vaccine. 2017. PMID: 28579232 Free PMC article.
References
-
- Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, Bai KY, Teng JLL, Tsang CCC, Wang M, et al. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 2012;86(7):3995–4008. doi:10.1128/JVI.06540-11. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous